HomeNewsBusinessCOVID-19 impact: FY21 H-1B quota unlikely to be reached in the first lottery, second round possible

COVID-19 impact: FY21 H-1B quota unlikely to be reached in the first lottery, second round possible

H-1B cap per year is 85,000, with 20,000 reserved for those who complete their advanced degree in the US

June 11, 2020 / 20:52 IST
Story continues below Advertisement

The US Citizenship and Immigration Services (USCIS) may go for a second lottery to fill the H-1B quota as firms shy away from filing petitions on the back of novel coronavirus, or COVID-19.

This, experts said, has also come at the back uncertainty over immigration reforms.

Story continues below Advertisement

The window for filing H-1B petitions opened on April 1 and companies were given three months to file petitions for those who were selected by the lottery.

This was the first time pre-registration for the H-1B lottery was undertaken. The newly implemented H1-B Electronic Registration Process mandated employers to register with the USCIS by March 20, after which the lottery process starts. After the lottery, the agency announces the potential beneficiaries who can start the application process.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show